News & Media

News & Media

Press releases

May 7, 2019
Kyn Therapeutics Strengthens Leadership Team with Key Appointments

February 4, 2019
Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer

January 18, 2019
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies

December 19, 2018
Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with Merck

March 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

In the news

Despite Buyout, Celgene Dealmaking Rolls On With Kyn, Obsidian Tie-Ups

Endpoints News
Celgene inks first deals since Bristol-Myers announced $74B buyout — bets $80M on immunometabolism

Boston Business Journal
Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup

Bloomberg Baystate Business: Biogen, Budget and ESG

view all Tweets


@LUNGevity is the nation's leading nonprofit dedicated to supporting those with lung cancer as well as all who are… http://ORqi7MhqQm

As Kyn continues to grow, we are actively looking for candidates for the newly created role of Director, intellectu… http://ZmVqc0BDa0

Interested in learning more about the scientific research that supports our Kynase program? If so, be sure to check… http://dnAGfACTya

The @GO2Foundation for Lung Cancer is the world’s leading organization dedicated to saving, extending, and improvin… http://BizPr1i4F8

Corporate fact sheet

download now

Media contact

David Rosen
Argot Partners


Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
50 Northern Avenue
7th Floor
Boston, MA 02210

Call us


Email us

Friend us